129 related articles for article (PubMed ID: 1665311)
1. Zardaverine: a cyclic AMP specific PDE III/IV inhibitor.
Schudt C; Winder S; Eltze M; Kilian U; Beume R
Agents Actions Suppl; 1991; 34():379-402. PubMed ID: 1665311
[TBL] [Abstract][Full Text] [Related]
2. Comparison of phosphodiesterase III, IV and dual III/IV inhibitors on bronchospasm and pulmonary eosinophil influx in guinea pigs.
Underwood DC; Kotzer CJ; Bochnowicz S; Osborn RR; Luttmann MA; Hay DW; Torphy TJ
J Pharmacol Exp Ther; 1994 Jul; 270(1):250-9. PubMed ID: 8035322
[TBL] [Abstract][Full Text] [Related]
3. Suppression of human eosinophil respiratory burst and cyclic AMP hydrolysis by inhibitors of type IV phosphodiesterase: interaction with the beta adrenoceptor agonist albuterol.
Dent G; Giembycz MA; Evans PM; Rabe KF; Barnes PJ
J Pharmacol Exp Ther; 1994 Dec; 271(3):1167-74. PubMed ID: 7996422
[TBL] [Abstract][Full Text] [Related]
4. Modulation of relaxant responses evoked by a nitric oxide donor and by nonadrenergic, noncholinergic stimulation by isozyme-selective phosphodiesterase inhibitors in guinea pig trachea.
Ellis JL; Conanan ND
J Pharmacol Exp Ther; 1995 Mar; 272(3):997-1004. PubMed ID: 7891355
[TBL] [Abstract][Full Text] [Related]
5. Zardaverine as a selective inhibitor of phosphodiesterase isozymes.
Schudt C; Winder S; Müller B; Ukena D
Biochem Pharmacol; 1991 Jun; 42(1):153-62. PubMed ID: 1648920
[TBL] [Abstract][Full Text] [Related]
6. The specific type III and IV phosphodiesterase inhibitor zardaverine suppresses formation of tumor necrosis factor by macrophages.
Schade FU; Schudt C
Eur J Pharmacol; 1993 Jan; 230(1):9-14. PubMed ID: 8381357
[TBL] [Abstract][Full Text] [Related]
7. Inhibition of phosphodiesterase IV and intracellular calcium levels in human polymorphonuclear leukocytes.
Villagrasa V; Navarrete C; Sanz C; Berto L; Perpiñá M; Cortijo J; Morcillo EJ
Methods Find Exp Clin Pharmacol; 1996 May; 18(4):239-45. PubMed ID: 8803956
[TBL] [Abstract][Full Text] [Related]
8. Differential effects of non-selective and selective phosphodiesterase inhibitors on human eosinophil functions.
Hatzelmann A; Tenor H; Schudt C
Br J Pharmacol; 1995 Feb; 114(4):821-31. PubMed ID: 7539697
[TBL] [Abstract][Full Text] [Related]
9. The effect of selective and non-selective phosphodiesterase inhibitors on allergen- and leukotriene C(4)-induced contractions in passively sensitized human airways.
Schmidt DT; Watson N; Dent G; Rühlmann E; Branscheid D; Magnussen H; Rabe KF
Br J Pharmacol; 2000 Dec; 131(8):1607-18. PubMed ID: 11139438
[TBL] [Abstract][Full Text] [Related]
10. Characterization of ORG 20241, a combined phosphodiesterase IV/III cyclic nucleotide phosphodiesterase inhibitor for asthma.
Nicholson CD; Shahid M; Bruin J; Barron E; Spiers I; de Boer J; van Amsterdam RG; Zaagsma J; Kelly JJ; Dent G
J Pharmacol Exp Ther; 1995 Aug; 274(2):678-87. PubMed ID: 7636728
[TBL] [Abstract][Full Text] [Related]
11. Attenuation by phosphodiesterase inhibitors of lipopolysaccharide-induced thromboxane release and bronchoconstriction in rat lungs.
Uhlig S; Featherstone RL; Held HD; Nüsing R; Schudt C; Wendel A
J Pharmacol Exp Ther; 1997 Dec; 283(3):1453-9. PubMed ID: 9400021
[TBL] [Abstract][Full Text] [Related]
12. Identification, characterization, and functional role of phosphodiesterase type IV in cerebral vessels: effects of selective phosphodiesterase inhibitors.
Willette RN; Shiloh AO; Sauermelch CF; Sulpizio A; Michell MP; Cieslinski LB; Torphy TJ; Ohlstein EH
J Cereb Blood Flow Metab; 1997 Feb; 17(2):210-9. PubMed ID: 9040501
[TBL] [Abstract][Full Text] [Related]
13. Potential use of selective phosphodiesterase inhibitors in the treatment of asthma.
Murray KJ; Eden RJ; England PJ; Dolan J; Grimsditch DC; Stutchbury CA; Patel B; Reeves ML; Worby A; Torphy TJ
Agents Actions Suppl; 1991; 34():27-46. PubMed ID: 1665307
[TBL] [Abstract][Full Text] [Related]
14. Differential modulation of cytokine production by drugs: implications for therapy in heart failure.
Matsumori A; Ono K; Sato Y; Shioi T; Nose Y; Sasayama S
J Mol Cell Cardiol; 1996 Dec; 28(12):2491-9. PubMed ID: 9004165
[TBL] [Abstract][Full Text] [Related]
15. The ability of phosphodiesterase IV inhibitors to suppress superoxide production in guinea pig eosinophils is correlated with inhibition of phosphodiesterase IV catalytic activity.
Barnette MS; Manning CD; Cieslinski LB; Burman M; Christensen SB; Torphy TJ
J Pharmacol Exp Ther; 1995 May; 273(2):674-9. PubMed ID: 7752069
[TBL] [Abstract][Full Text] [Related]
16. Identification of PDE isozymes in human pulmonary artery and effect of selective PDE inhibitors.
Rabe KF; Tenor H; Dent G; Schudt C; Nakashima M; Magnussen H
Am J Physiol; 1994 May; 266(5 Pt 1):L536-43. PubMed ID: 7515580
[TBL] [Abstract][Full Text] [Related]
17. Effects of isoenzyme-selective inhibitors of cyclic nucleotide phosphodiesterase on microvascular leak in guinea pig airways in vivo.
Raeburn D; Karlsson JA
J Pharmacol Exp Ther; 1993 Dec; 267(3):1147-52. PubMed ID: 8263775
[TBL] [Abstract][Full Text] [Related]
18. Evaluation of the effect of phosphodiesterase on equine platelet activation and the effect of antigen challenge on platelet phosphodiesterase activity in horses with recurrent airway obstruction.
Dunkel B; Rickards KJ; Werling D; Page CP; Cunningham FM
Am J Vet Res; 2010 May; 71(5):534-40. PubMed ID: 20433379
[TBL] [Abstract][Full Text] [Related]
19. CDP840: a novel inhibitor of PDE-4.
Perry MJ; O'Connell J; Walker C; Crabbe T; Baldock D; Russell A; Lumb S; Huang Z; Howat D; Allen R; Merriman M; Walls J; Daniel T; Hughes B; Laliberte F; Higgs GA; Owens RJ
Cell Biochem Biophys; 1998; 29(1-2):113-32. PubMed ID: 9631241
[TBL] [Abstract][Full Text] [Related]
20. Role of phosphodiesterases in the regulation of endothelial permeability in vitro.
Suttorp N; Weber U; Welsch T; Schudt C
J Clin Invest; 1993 Apr; 91(4):1421-8. PubMed ID: 8386187
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
